The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. is reported to have 931,000 shares of its Common Stock, par value $0.0001 per share, beneficially owned by Opaleye, L.P., Opaleye Management Inc., and James Silverman (collectively the reporting persons). Based on 16,956,415 shares of Common Stock outstanding as of May 1, 2026, this represents 5.49% of the class.
The Fund directly holds the 931,000 shares, while Opaleye Management Inc., as investment adviser to the Fund, and James Silverman, as the controlling person of the adviser, may be deemed to share voting and dispositive power over these shares. The reporting persons disclaim that this filing constitutes an admission of beneficial ownership for purposes of Section 13 of the Securities Exchange Act of 1934 or otherwise.
Q32 Bio Inc. is registering the resale of up to 6,875,000 shares of common stock by existing investors under a shelf prospectus. This includes 6,725,000 shares already outstanding and 150,000 shares issuable upon exercise of pre-funded warrants issued in a May 26, 2026 private placement.
The company is not selling shares in this offering and will receive no proceeds from resale, though it may receive nominal cash if pre-funded warrants are exercised. Q32 Bio is a clinical-stage biotech focused on bempikibart for alopecia areata and related autoimmune conditions. It previously restructured to prioritize bempikibart and sold ADX-097 rights to Akebia Therapeutics. The stock trades on Nasdaq as “QTTB” and closed at $15.21 on July 27, 2026, with 29,763,999 shares outstanding as of July 16, 2026.
Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036. The options vest and become exercisable in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. This amendment updates a Form 4 filed on June 16, 2026 solely to correct the number of options awarded.
Q32 Bio Inc. director Sven Ante Lundberg reported a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. The options vest in full upon the earlier of June 12, 2027 or the next annual stockholders’ meeting, and this Form 4/A corrects the number of options originally reported.
Q32 Bio Inc. director Kathleen LaPorte received a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. This amendment corrects the previously reported grant size. The options vest in full on the earlier of June 12, 2027 or the next annual meeting of stockholders, subject to her continued service.
Q32 Bio Inc. director Mark T. Iwicki reported a compensation award of stock options for 10826.0000 shares of common stock, granted on June 12, 2026 at an exercise price of $12.6400 per share and expiring June 11, 2036. The options vest in full on the earlier of June 12, 2027 or the issuer's next annual meeting of stockholders, subject to his continued service. This Form 4 amendment corrects the number of options previously reported for this grant.
An amended Form 4 for Q32 Bio Inc. reports that director and 10% owner Diyong Xu received a grant of 10,826 stock options on June 12, 2026 at a $12.64 exercise price, vesting by June 12, 2027 or the next annual meeting, with benefits required to be passed through to specified OrbiMed investment entities.
Q32 Bio Inc. director Isaac Manke received a grant of stock options for 10,826 shares of common stock on June 12, 2026 at an exercise price of $12.64 per share, expiring on 2036-06-11. This amendment corrects the option amount previously reported. The options vest in full on the earlier of June 12, 2027 or the issuer’s next annual meeting of stockholders, subject to his continued service.
Q32 Bio Inc. director David S. Grayzel received a corrected grant of stock options covering 10,826 shares of common stock at an exercise price of $12.64 per share, expiring on June 11, 2036.
The options vest in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.